Ludiomil

Quick links to important sections

Ludiomil

Selected form

Method of action: Antidepressant, Psychoanaleptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ludiomil

Quick Facts

Property Description
Active Ingredient Maprotiline hydrochloride
Form Oral tablet (various strengths)
Pharmacological Class Tetracyclic Antidepressant (TeCA)
General Purpose Mood regulation and emotional balance
Origin Chemically synthesized prescription-only medication (Rx status)

Ludiomil is the brand name for the prescription medicine maprotiline, a compound officially classified as a tetracyclic antidepressant (TeCA). Its primary function is to influence the balance of certain naturally occurring chemicals in the brain, helping to regulate mood and emotional stability.


What Type of Medicine is Ludiomil?

Ludiomil belongs to a group of psychiatric medications known as tetracyclic antidepressants (TeCAs), a distinct pharmacological class. This classification is based on its four-ring chemical structure, which differs from older tricyclic antidepressants (TCAs). The active substance, maprotiline hydrochloride, is a chemically synthesized compound (not natural or herbal in origin) and is supplied as an oral tablet for consistent systemic delivery. The medication holds prescription-only status (Rx), reflecting the need for medical oversight during its use.

Why is Maprotiline Used?

Maprotiline is used to help restore a more stable balance of key neurotransmitters, which are chemical messengers in the brain. Its action involves primarily enhancing the availability of norepinephrine, thereby influencing pathways associated with mood, focus, and alertness. Maprotiline acts as a highly selective inhibitor of norepinephrine reuptake. This is its key differentiating factor, making it a specialized choice compared to modern antidepressants that often target serotonin.

Maprotiline is used to assist individuals in achieving a more balanced emotional state, particularly in managing mood-related disorders where symptoms of anxiety or agitation are present. In simple terms, its benefit is helping people regain emotional stability and a sense of well-being.

Regulatory References

  1. MedlinePlus: Maprotiline Drug Information

What side effects are possible with Ludiomil?

Ludiomil: Possible Side Effects and Safety Information

FDA Black Box Warning and Serious Risks

Ludiomil (maprotiline) carries a U.S. Food and Drug Administration (FDA) Black Box Warning regarding the increased risk of suicidal thoughts and behavior (suicidality) in children, adolescents, and young adults (up to age 24) when starting therapy or following dose changes. Close monitoring for clinical worsening and unusual behavioral changes is required for all patients on antidepressant therapy.

Serious, potentially life-threatening risks include seizures (convulsions), which may occur even in patients without a prior history. The drug may also affect the heart, with risks including cardiac conduction defects, arrhythmias, myocardial infarction, and stroke.

Common Adverse Reactions

The most commonly reported adverse reactions are often related to the drug's anticholinergic and sedative properties. These include drowsiness (up to 16%), dry mouth (up to 22%), dizziness, tremor, headache, blurred vision, constipation, and weakness/fatigue.

Contraindications and Safety Considerations

Ludiomil is contraindicated for concurrent use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of severe reactions, and it should not be used during the acute recovery phase following a myocardial infarction. It is also contraindicated in patients with known or suspected seizure disorders.

Population-specific caution is necessary for the elderly, who may be more susceptible to adverse effects such as confusion, dizziness, and anticholinergic effects. Patients with a history of cardiovascular disease or narrow-angle glaucoma require careful monitoring due to the potential for severe cardiac or ocular adverse events, respectively. Safety monitoring should specifically target cardiovascular function and seizure risk, in addition to the mandated vigilance for suicidality.

Overdose and Emergency Response

The official regulatory documentation classifies maprotiline overdosage as a medical emergency due to its documented potential for severe central nervous system (CNS) and cardiovascular toxicity.

Domain Official Regulatory Statements
Documented Overdose Presentations: Manifestations may include convulsions (seizures), severe drowsiness, agitation, fast or irregular heartbeat, severe hypotension, fever, and trouble breathing.
Physiological Systems Affected: Toxicity is primarily documented to affect the Central Nervous System (leading to coma) and the Cardiovascular System (leading to arrhythmias).
Population-specific Notes: Children who may have ingested an overdosage must be hospitalized and kept under close surveillance. The elderly face an increased risk of severe cardiac effects.
When Medical Help is Required: Individuals must seek immediate medical attention and contact the poison control center right away. All suspected cases require hospital monitoring.

Severity Classification: The overdose profile is designated as life-threatening due to the potential for fatal outcomes, including cardiac arrest and deep coma. Management is strictly symptomatic and supportive as no specific antidote is known. Continuous observation, including Electrocardiogram (ECG) monitoring for conduction abnormalities, is required to manage acute complications.


Resulting Overdose Structure: Official labeling defines the overdose as a high-risk scenario due to the severe and sudden nature of CNS and cardiac effects. The presence of these life-threatening risks mandates that all patients, regardless of age, must be immediately transported for hospital observation and provided with supportive care, as specified by regulatory guidance.

Therapeutic Uses of Ludiomil

What Ludiomil Treats: Main Uses and Benefits

Ludiomil (maprotiline) is commonly used across conditions presenting with acute episodes of depressive illness, including Major Depressive Disorder (MDD) and Depressive Neurosis (Dysthymia). It helps address the core emotional burden of persistent sadness, loss of interest (anhedonia), and feelings of worthlessness. It is considered relevant in conditions where functional stability becomes affected and assists with maintaining a sense of stability when symptoms are more noticeable during recurrent episodes of depression.

A key therapeutic application is relevant for managing symptoms that interfere with daily comfort, such as depression associated with prominent anxiety and agitation. The medication is relevant in contexts marked by increased discomfort or tension, which may assist with managing manifestations like inner tension and restlessness. Ludiomil is helpful in situations where multiple symptoms occur together, including associated sleep disturbances (insomnia). The medicine is further relevant in settings requiring additional symptomatic support, such as when groups of symptoms in treatment-resistant depression appear suddenly or fluctuate. It is also relevant for easing symptoms related to physical discomfort, such as certain types of chronic neuropathic pain.


Quick Fact Block

Quick Fact: Relief for Key Symptom Clusters Description
Mood Helps address persistent sadness and emotional burden.
Anxiety/Tension May assist with easing inner tension and restlessness associated with depression.
Sleep Supports the handling of associated insomnia and sleep disturbances.
Pain Relevant for easing symptoms of certain types of chronic neuropathic pain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ludiomil? (Maprotiline)

The official eligibility for Ludiomil is strictly defined by regulatory documents, distinguishing between approved use, conditional use, and absolute prohibitions (contraindications).


Absolute Contraindications

Ludiomil must not be used by patients with:

  • A known hypersensitivity to maprotiline.
  • Known or suspected seizure disorders, including epilepsy.
  • The acute recovery phase following a myocardial infarction or with acute congestive heart failure.
  • Existing severe hepatic damage or severe renal damage.
  • Concomitant use of a Monoamine Oxidase (MAO) inhibitor.

Age-Group Eligibility

Age Group Regulatory Status
Pediatric (Under 18) Not approved; safety and effectiveness are not established in this population.
Adults The approved population for depressive illness.
Older Adults (Geriatric) Requires special consideration; lower dosages are generally recommended due to increased sensitivity.

Conditional Use

Use requires extreme caution and close surveillance in patients with a history of cardiovascular disease (e.g., conduction defects), narrow-angle glaucoma, urinary retention, or those with hyperthyroidism.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ludiomil (maprotiline) has officially documented interaction patterns based on regulatory prescribing information, which define required constraints for co-administration.


Contraindicated Combinations and Timing Rules

Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the potential for a severe, potentially fatal reaction. A mandatory 14-day washout period must elapse after discontinuing an MAOI before starting Ludiomil, and vice versa. Similarly, treatment must be separated by 24 hours after the last dose of MAOI-like agents such as Linezolid or intravenous Methylene Blue.


Documented Pharmacodynamic and Exposure Effects

Co-administration with other substances can lead to additive effects. The combination with Central Nervous System (CNS) depressants, including alcohol, is documented to result in an additive CNS depressant effect. There is also a formally noted risk of potentiating cardiovascular effects when combined with sympathomimetic agents. Co-use with drugs that lower the seizure threshold, such as phenothiazines, increases the documented risk of convulsions.

Pharmacokinetic interactions with select medicines like paroxetine or bupropion may alter plasma exposure, requiring monitoring and potential modification of the dosage of Ludiomil or the co-administered agent.

Mechanism of Action

Ludiomil (Maprotiline) acts primarily by inhibiting the Sodium-dependent Norepinephrine Transporter (NET), preventing the clearance of norepinephrine from nerve synapses. This selective blockade enhances the concentration of norepinephrine, sustaining and strengthening signaling in central adrenergic circuits or pathways associated with mood signaling. This requires several weeks for the necessary neuroadaptive changes to occur and complete the neuroadaptive process. The drug also engages in high-affinity antagonism at the central Histamine H1 receptor, which suppresses pathways of wakefulness and results in functional dampening of central arousal pathways. Concurrently, Maprotiline blocks Alpha-1 (alpha1) and Muscarinic Receptors, which modulates peripheral autonomic functions like vascular tone and secretions, shaping the combined physiological activity.

Dosage and Administration Information

How Ludiomil is Used: Official Administration Guidelines

Ludiomil (maprotiline) is a prescription medication administered exclusively via the oral route as a tablet. Administration follows a structured, phased approach to dosing and usage.


Administration Scope

Feature Standardized Guideline
Route of Administration Oral tablet. Tablets must be swallowed whole with liquid.
Timing in Relation to Meals May be taken with or without food.
Dosing Frequency Typically administered once daily or in divided doses. The single daily dose is often taken at bedtime.
Missed Dose Rule For once-daily dosing, a missed dose should not be taken in the morning if due at bedtime.
Age-Group Rules Geriatric Patients (over 60) must begin with a lower initial dose, typically 25 mg daily. Pediatric use is not recommended.

Standardized Dosing and Procedure

The administration of Ludiomil follows a protocol of gradual initiation and adjustment to reach the effective therapeutic level. This process involves specific parameters for dosage increments.

Dosing and Procedural Rule Guideline Detail
Adult Outpatient Dosing Initial dose of 75 mg daily (single or divided). Maintenance is typically 75 mg to 150 mg daily.
Adult Inpatient Dosing Initial dose may be higher, ranging from 100 mg to 150 mg daily. The absolute maximum dose is 225 mg per day.
Procedural Condition Therapy must be started at the lowest possible dosage and must be maintained for at least two weeks before any gradual increase, which should be done in 25 mg increments.

This structured approach defines the standardized, phased initiation of the medication, ensuring the protocol is non-individualized and provides a descriptive overview of dosage requirements.

Recent Clinical Evidence

Research evidence / Overview of studies for Ludiomil

Evidence for use in Depressive Illness (Major Depression, Anxiety, and Agitation)

The primary body of research for maprotiline was studied for conditions characterized by fluctuating or episodic manifestations of depressive illness. This research base largely consists of historical Randomized Controlled Trials (RCTs) and large-scale observational studies that were evaluated in various adult populations. Research explored short-term symptom changes over defined time intervals, typically ranging from three to eight weeks.

Studies used standardized scales to measure outcomes related to systemic or functional imbalance, such as changes in the severity of core depressive symptoms like persistent sadness and loss of interest. Research also examined outcomes describing episodic or acute changes in associated symptoms, including inner tension, anxiety, and sleep disturbances. Findings describe patterns observed in the studies across these different symptom axes, often involving comparisons to a placebo or to other medications.

Evidence for use in Chronic Neuropathic Pain

Maprotiline was evaluated in studies of certain forms of chronic neuropathic pain, such as pain related to diabetic polyneuropathy or post-herpetic neuralgia. Research examining outcomes related to the measurement of specific neuropathic pain symptoms consists of a smaller number of controlled trials. These studies monitored patient-reported outcomes describing perceived discomfort and changes in symptom intensity or variability over periods of several weeks. The overall certainty remains low when relying on maprotiline-specific data for this application.

Long-term Studies and Durability of Follow-up

Research has explored outcomes beyond the acute treatment phase. Maintenance trials monitored the occurrence and frequency of relapse or recurrence of symptoms, with follow-up durations observed in the studies sometimes reaching up to one year. However, the follow-up durations were limited in many studies, and long-term effects are not fully established for all populations.

Research in Special Populations

Evidence was evaluated in specific groups, particularly older adults (geriatric patients). Studies in this population examined response patterns and the change in symptom patterns, to provide context for research in this age group. Regarding pediatric populations (children and adolescents), authoritative sources indicate that the scope of clinical research is limited, and studies evaluating outcomes in this group remain insufficient.

Key Studies & References

  1. Maprotiline in pain-depression

Frequently Asked Questions (FAQ)

Common questions about Ludiomil (FAQ)


Q: How is Ludiomil different from SSRIs like Zoloft or Prozac?

A: Ludiomil (maprotiline) is officially classified as a tetracyclic antidepressant (TeCA), which distinguishes it from modern medications like SSRIs (Selective Serotonin Reuptake Inhibitors). The key difference is its mechanism of action: Ludiomil is a highly selective inhibitor of norepinephrine reuptake, boosting the levels of that specific neurotransmitter, whereas SSRIs primarily target serotonin.


Q: How long does it typically take for Ludiomil to start working?

A: Official information indicates that Ludiomil has a relatively long half-life, meaning it stays in the body for a considerable time. Regulatory protocols indicate that because of this, the starting dosage is often held for at least two weeks before adjustment. The process of neuroadaptive change, which leads to the therapeutic response, typically takes several weeks.


Q: Can Ludiomil affect your sleep patterns?

A: Yes, regulatory documents indicate Ludiomil can affect sleep. This is due to one of its actions—antagonizing the central Histamine H1 receptor—which suppresses pathways of wakefulness and can result in drowsiness. While official information mentions that Ludiomil was studied in relation to sleep disturbances, drowsiness is also listed as a commonly reported side effect.


Q: Do you have to take Ludiomil with food?

A: According to the official prescribing information, Ludiomil tablets may be taken with or without food. The timing in relation to meals does not generally affect the medication's absorption.


Q: Do people typically take Ludiomil in the morning or at night?

A: The official administration guidelines state that the single daily dose is often taken at bedtime. This timing is often utilized, which is consistent with the medication's tendency to cause drowsiness.


Q: Can Ludiomil affect your ability to drive or operate machinery?

A: Yes, official warnings state that Ludiomil may cause side effects like drowsiness, blurred vision, or dizziness. Due to these potential effects, regulatory information cautions against driving, operating complex machinery, or engaging in other potentially hazardous activities if one experiences these effects.


Q: How long does Ludiomil stay in your system after you stop taking it?

A: Studies show that maprotiline has a long biological half-life, typically ranging from approximately 27 to 58 hours in humans. It generally takes about five half-lives for a medication to be almost completely eliminated from the body after the last dose.


Q: Can Ludiomil cause changes in blood sugar levels?

A: While not frequently listed as a common adverse reaction, official information related to some metabolic studies suggests that treatment with maprotiline may be associated with changes in measures of insulin resistance.


Q: Can Ludiomil help with anxiety as well as depression?

A: Yes. The official indications for maprotiline include the treatment of depressive illness. It is also indicated for the relief of anxiety associated with depression.


Q: Are there any long-term side effects associated with Ludiomil use?

A: Regulatory data indicates that common side effects, such as dry mouth and constipation, may persist with continued use. For long-term use, close monitoring for effects on the heart is typically recommended, in addition to the mandated vigilance required by the Black Box Warning for younger adults.


Q: What happens if I forget to take a dose of Ludiomil?

A: For the typical once-daily dosing regimen taken at night, the official guidelines specifically state that a missed dose should not be taken in the morning.


Q: Can Ludiomil interact with herbal supplements like St. John's Wort?

A: Regulatory guidance has noted that St. John's Wort should be avoided with certain antidepressants. This is due to the potential for interactions that could increase the risk of adverse effects.


Q: Can Ludiomil be used long-term?

A: Research has explored the long-term use of Ludiomil in maintenance trials that sometimes lasted up to one year to monitor for symptom recurrence. However, authoritative sources note that long-term effects beyond these study durations are not fully established for all patient populations.


Q: Can Ludiomil affect appetite?

A: Yes, changes in appetite are listed as a possible side effect in patient information. Both increased appetite, which can lead to weight gain, and, less commonly, weight loss have been reported.


Q: Does Ludiomil interact with birth control pills?

A: Specific studies detailing an interaction with hormonal contraceptives are not widely cited in the core regulatory labeling. However, maprotiline's drug profile indicates it may affect enzymes that metabolize other medications.


Q: Is Ludiomil more activating or sedating?

A: Ludiomil is generally considered to be associated with a sedating effect. This is supported by its mechanism of action, which involves the potent blockade of the Histamine H1 receptor, and the frequent reporting of drowsiness as a common adverse reaction.


Q: Does Ludiomil require blood tests to monitor levels?

A: Official labeling requires regular monitoring for safety, particularly of cardiovascular function and seizure risk. While not universally mandatory, clinical studies have established target steady-state blood levels, which serves as a basis for therapeutic drug monitoring (TDM).


Q: Is Ludiomil safe to take during pregnancy?

A: The US FDA assigned maprotiline to Pregnancy Category B. This means that animal studies have not demonstrated a risk to the fetus, but there are no adequate and controlled studies conducted in pregnant women. The official product information indicates that use during pregnancy is recommended only if the potential benefit justifies the potential risk to the fetus.

How should Ludiomil be stored and disposed of?

How to Store and Dispose of Ludiomil (Maprotiline Hydrochloride)

Ludiomil tablets must be stored at Controlled Room Temperature, specifically between 20°C and 25°C (68°F and 77°F). Storage must occur away from excess heat and moisture. To maintain product stability, the medication must be kept in a tight, light-resistant container, as specified in regulatory labeling.

Official Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature (20°C–25°C)
Protection Keep in a tight, light-resistant container
Child Safety Store out of the reach of children
Disposal Discard according to official guidance for unused or expired medicines

All prescription medication must be kept out of the reach of children. Unused or expired Ludiomil must be disposed of following official government guidance, such as utilizing recognized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ludiomil found in:

A-Z Index: